Results 151 to 160 of about 276,514 (189)
British Journal of Haematology, EarlyView.Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
British Journal of Haematology, EarlyView.A comparison between bead‐based and cell‐based assays for autoantibody detection in childhood neutropenia revealed substantial discordance between platforms. Bead‐based methods should be complemented with cell‐based methods for optimal diagnostic sensitivity. Incorporating pro‐LL‐37 and ANC measurements into the clinical workup of childhood neutropenia
Paul Ratcliffe +3 more
wiley +1 more source
Long‐term oncological outcomes from a prospective cohort of patients with localised prostate cancer
BJU International, EarlyView.Objectives To report long‐term oncological outcomes for men with clinically localised prostate cancer (PCa) treated with contemporary modalities in a population‐based United States cohort. Patients and Methods The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study prospectively enrolled men with clinically localised PCa from ...
Avi S. Baskin +17 more
wiley +1 more source
Brain Pathology, EarlyView.Resource level‐based recommendations on practical diagnostic strategies for medulloblastomas and other CNS embryonal tumors are provided. Abstract WHO CNS5 mandates integrated histo‐molecular classification of medulloblastomas (MBs) and other CNS embryonal tumors. However, advanced molecular diagnostics remain inaccessible in many low‐ and lower‐middle‐
Chitra Sarkar +12 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
Cancer Science, EarlyView.ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba +21 more
wiley +1 more source
Proportion of Screen‐Detected Gastrointestinal Cancers From the National Cancer Registry in Japan
Cancer Science, EarlyView.Using the data from the Japanese National Cancer Registry, screen‐detected gastrointestinal cancers accounted for roughly 20% of all detected routes. We also found that the proportion of screen‐detected cancers was positively correlated with screening participation rates, supporting screen‐detected cancer proportion as a valuable indicator for ...
Ryuji Okamoto +6 more
wiley +1 more source
Advances in Radiotherapy for Neoadjuvant Therapy of Stage III Non‐Small Cell Lung Cancer
Cancer Science, EarlyView.This review summarizes three neoadjuvant radiotherapy techniques for stage III NSCLC, highlighting SFRT's low‐toxicity dual immune‐tumor control benefits and radioimmunotherapy's superior pathological response to guide precise multimodal treatment. ABSTRACT This review aims to systematically summarize the mechanisms of action, clinical evolution, and ...
Qinrong Mao +5 more
wiley +1 more source
Cancer Science, EarlyView.Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui +15 more
wiley +1 more source